Clinical trial · Interventional
Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer
Feasibility of Targeted Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Patients With Early-stage Non-small Cell Lung Cancer
NCT06301295CI-TRIAL-00105288active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ultarthin bronchoscopy with intratumoral washing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ultrathin bronchoscopy with intratumoral washing
- description
- Each subject suspected of early-stage lung cancer will undergo bronchooscopic procedure for generic alteration with Next Generation Sequencing.
- interventionNames
- Diagnostic Test: Ultarthin bronchoscopy with intratumoral washing
Primary outcomes (1)
- measure
- The diagnostic accuracy of genetic alterations in intratumoral washing fluid using Next Generation Sequencing
- timeFrame
- through study completion, an average of 1 year
- description
- Diagnostic accuracy is defined as the number of true positive and true negative genetic alterations detected by Next Generation Sequencing, divided by the total number of intratumoral washing attempts using ultrathin bronchoscopy.
Secondary outcomes (5)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
1. Inclusion Criteria: * Age ≥ 20 years * Obtained written informed consent * Subjects suspected of having resectable lung cancer on computed tomography * Subjects without contraindication to brochoscopy * Subjects planning to undergo surgery for suspected lung cancer and opting for tissue or liquid biopsy for genetic alteration using Next Generation Sequencing 2. Exclusion Criteria: * Subjects who withdraw informed consent * Subjects who are unable to undergo liquid biopsy (plasma) and tissue biopsy - for genetic alteration with Next Generation Sequencing based on the investigator's judgement * Subjects diagnosed with a cancer other than non-small cell lung cancer from the lung tissue lesion * Subjects diagnosed with a benign lesion from the lung tissue lesion
References
Publications (0)
Data not yet available
No reference posted for this study.